机译:在复发多个骨髓瘤中,有或没有低剂量地塞米松的Carfilzomib 56mg / m 2的2个单中心研究
Myeloma Service Memorial Sloan-Kettering Cancer Center 1275 York Ave Box 539 New York NY 10065;
Epidemiology and Biostatistics Memorial Sloan-Kettering Cancer Center New York NY United States;
Epidemiology and Biostatistics Memorial Sloan-Kettering Cancer Center New York NY United States;
Department of Medicine Weill Medical College of Cornell University New York NY United States;
Myeloma Service Memorial Sloan-Kettering Cancer Center 1275 York Ave Box 539 New York NY 10065;
Myeloma Service Memorial Sloan-Kettering Cancer Center 1275 York Ave Box 539 New York NY 10065;
Department of Medicine Memorial Sloan-Kettering Cancer Center New York NY United States;
Department of Medicine Memorial Sloan-Kettering Cancer Center New York NY United States;
Department of Medicine Weill Medical College of Cornell University New York NY United States;
Department of Medicine Weill Medical College of Cornell University New York NY United States;
Department of Medicine Weill Medical College of Cornell University New York NY United States;
Department of Medicine Weill Medical College of Cornell University New York NY United States;
机译:在复发多个骨髓瘤中,有或没有低剂量地塞米松的Carfilzomib 56mg / m 2的2个单中心研究
机译:Pembrozumab与Carfilzomib和低剂量地塞米松的复发或难治性多发性骨髓瘤联合:I阶段的队列2次键演示 - 023研究
机译:复发和/或难治性多发性骨髓瘤患者单用卡非佐米或与小剂量地塞米松联用30分钟输注的I期研究
机译:耐久性耐久性与多发性骨髓瘤复发疗法
机译:Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物,最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
机译:卡非佐米56 mg / m2联合或不联合低剂量地塞米松治疗复发性多发性骨髓瘤的2期单中心研究
机译:Carfilzomib,Lenalidomide和低剂量地塞米松的相IB剂量 - 升级研究(PX-171-006)在复发或进行多发性骨髓瘤中